Provided by Tiger Trade Technology Pte. Ltd.

Zenas BioPharma Inc.

32.04
-0.2800-0.87%
Volume:124.35K
Turnover:4.01M
Market Cap:2.09B
PE:-3.54
High:32.73
Open:32.20
Low:31.77
Close:32.32
52wk High:44.60
52wk Low:13.50
Shares:65.18M
Float Shares:47.02M
Volume Ratio:0.53
T/O Rate:0.26%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-9.0522
EPS(LYR):-8.4448
ROE:-199.04%
ROA:-34.42%
PB:8.45
PE(LYR):-3.79

Loading ...

Morgan Stanley Reaffirms Their Hold Rating on Zenas BioPharma, Inc. (ZBIO)

TIPRANKS
·
Apr 08

Zenas Biopharma director Hongbo Lu acquires ZBIO common shares worth $0.1 million

Reuters
·
Apr 03

Major Insider Move Signals Growing Confidence in Zenas BioPharma’s Future

TIPRANKS
·
Apr 02

Fairmount Healthcare Fund II acquires Zenas BioPharma shares worth $3 million

Reuters
·
Apr 02

Zenas BioPharma Raises Capital via Notes and Equity Offering

TIPRANKS
·
Apr 01

Zenas BioPharma director buys $1.5M in common stock

TIPRANKS
·
Apr 01

Zenas BioPharma director Hongbo Lu reports $1.5 million common share acquisition

Reuters
·
Apr 01

Top Midday Decliners

MT Newswires Live
·
Mar 28

Zenas BioPharma Tumble on Pricing of Convertible-Note, Stock Public Offerings

Dow Jones
·
Mar 28

BUZZ-U.S. STOCKS ON THE MOVE-Entergy, IDEX Corp, Quanta Services

Reuters
·
Mar 27

Zenas Biopharma Announces Pricing of Concurrent Public Offerings of 2.50% Convertible Senior Notes Due 2032 and Common Stock With Aggregate Gross Proceeds of $300.0 Million

THOMSON REUTERS
·
Mar 27

Stocks to Watch: Datacentrex, Unity Software, Veritone, Zenas BioPharma

Dow Jones
·
Mar 27

BUZZ-Zenas BioPharma drops on convertible, equity offerings

Reuters
·
Mar 27

Zenas Biopharma announces underwritten public offering of convertible senior notes due 2032; terms are set at pricing

Reuters
·
Mar 27

Zenas Biopharma Inc - Proceeds to Support Obexelimab U.S. Launch, Pipeline Advancement, and General Corporate Purposes

THOMSON REUTERS
·
Mar 27

Zenas BioPharma Announces Proposed Concurrent Public Offerings of Convertible Senior Notes Due 2032 and Common Stock

GlobeNewswire
·
Mar 27

Zenas BioPharma Advances Phase 3 Orelabrutinib Trial in Progressive Multiple Sclerosis

TIPRANKS
·
Mar 21

Wedbush Sticks to Its Buy Rating for Zenas BioPharma, Inc. (ZBIO)

TIPRANKS
·
Mar 17

Zenas BioPharma Is Maintained at Equal-Weight by Morgan Stanley

Dow Jones
·
Mar 17

Zenas BioPharma Price Target Maintained With a $44.00/Share by HC Wainwright & Co.

Dow Jones
·
Mar 17